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Streptococcus pneumoniae (pneumococ-
cus [Pnc]) is a common bacterial agent found
in mild mucosal as well as severe systemic
infections. Local infections, such as acute
otitis media, are rather common; every child
has at least one during the first 2 years of life
(1), and Pnc is the causative agent in
approximately half of the bacterial culture-
positive cases (2). Pneumonia is another
disease often caused by Pnc, both in
industrialized and developing countries.
Pneumonia, which causes more than one
million deaths per year, is the most common
cause of childhood death in the developing
world (3); pneumococcal pneumonia is a
serious problem among the elderly in
industrialized countries. Pnc also causes
frequent invasive infections, especially among
children. In Finland, the incidence of
bacteremic pneumococcal infections at 0 to 4
years of age has been 24.2 per 100,000 per
year (4). The corresponding rate was 42 per
100,000 per year in Israel (5) and 66 per
100,000 per year in the United States (6). In
addition to the young and the elderly, some
of the other groups at increased risk for Pnc
infection are patients with chronic cardiac or
pulmonary diseases, immunocompromised
patients, and especially persons with func-
tional or anatomic asplenia (7).
The treatment of recently emerged Pnc
strains that are resistant to penicillin and
other antibiotics (8) is becoming a challenge.
Because of the high rates of illness and death
associated with pneumococcal infections and
the rapidly increasing resistance of organ-
isms that cause these infections to antimi-
crobial drugs, development and use of
effective pneumococcal vaccines is of high
priority. The progress has been rapid; in
addition to polysaccharide(PS)-protein con-
jugate vaccines, vaccines containing pneu-
mococcal proteins are also being developed.
Pneumococcal Capsular Polysaccharide
Vaccine
Pnc can be divided into at least 90
serotypes according to the structure of the
PS in the capsule surrounding the bacte-
rium. The capsule seems to be the most
important virulence factor; all strains
isolated from infections are encapsulated.
The capsule helps the bacterium escape the
host defense mechanisms. However, only a
small fraction of all capsular types are
common causes of pneumococcal infections.
The list of the most common groups/types (4,
6, 7, 9, 14, 18, 19, and 23) that cause
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childhood infections is similar in most parts
of the world. Types 1 and 5 are, however,
more common in the developing world than
in industrialized countries (9).
Antibodies to capsular PSs protect from
infection by opsonizing Pnc for phagocytosis
by neutrophils. A capsular PS vaccine
containing 23 of the most common serotypes/
groups has proven protective in immunocom-
petent adults and in some groups at risk
(7,10,11); it has also been shown to have an
impact on death rates due to pneumonia in
Papua New Guinea (12). Among the
immunocompromised and in preventing
acute otitis media, (13) its efficacy has been
only marginal.
The reason for the vaccine’s poor
immunogenicity and its lack of efficacy in
children is thought to be the nature of the PS
antigen. PS antigens are type 2 T-cell
independent (TI) antigens, which stimulate
mature B cells without the help of T cells. In
humans, the B cells of newborns do not
respond to most of the PS antigens.
Responsiveness develops only slowly during
the first years of life. Furthermore, the TI
antigens do not induce immunologic memory
and the maturation of the immune response;
anti-PS antibodies have low avidity and the
switch from one isotype to another does not
happen even after repeated immunizations.
The TI antigens induce mainly IgM re-
sponses, especially in mice. However, in
humans the response also contains the IgG
and IgA components (14). Furthermore, the
IgG response to PS antigens contains a
greater proportion of IgG2 (15,16) than
found in a response to protein antigens. The
lack of memory has some important implica-
tions for the vaccination. Because of the
rapid decline of antibodies, revaccination is
often necessary (7).
Pneumococcal Protein Vaccine Candidates
Several ways have been and are being
tried to solve the problem of poor immunoge-
nicity of pneumococcal PS vaccines in
infancy. In addition to the capsule, other
pneumococcal virulence factors have been
considered as promising vaccine candidates
or as carrier proteins in pneumococcal
conjugate vaccines (see above). The prime
vaccine candidates are enzymes and toxins
that are excreted or released after the
bacterium has autolyzed or surface proteins
whose exact functions are not known.
Pneumococcal proteins studied as potential
vaccines include neuramididase, autolysin,
pneumolysin, pneumococcal surface protein
A (PspA), and pneumococcal surface adhesin
A (PsaA) (17-19).
Pneumolysin is a cytolytic toxin produced
by all types of Pnc. In mice, immunization
with inactivated pneumolysin or recombi-
nant pneumolysin toxoid offers at least
partial protection or enhanced survival when
challenged with Pnc (20,21). PspA is a
surface protein present in all clinically
relevant pneumococcal strains. PspAs from
different pneumococcal strains vary serologi-
cally. However, many PspA antibodies cross-
react with PspAs from unrelated strains.
Furthermore, active immunization of mice
with PspA generates protective immune
response against diverse pneumococcal
strains (22). Truncated PspAs, expressed as
recombinant proteins, are also immunogenic
in mice and can elicit cross-protection (18).
Pneumococcal Conjugate Vaccines
Another approach to solving the poor
immunogenicity of the capsular PS antigens
has already moved to the clinical phase-III
trials. This approach is based on the 1929
findings of Goebel and Avery (23), who
showed that covalent coupling of haptens to a
protein carrier improves the immunogenicity
of the hapten. In this way, the anti-PS
response gets T-cell dependent characters:
there is development of immunologic memory
and maturation of the immune response.
This is seen as an increase in the antibody
concentrations and the antibody affinity and
as a switch in the isotype distribution after
repeated immunizations. This approach has
been used successfully to prepare vaccines
against Haemophilus influenzae type b
(Hib); the incidence of Hib infection has
decreased drastically wherever these conju-
gate vaccines have been used (24).
The PS antigen in a conjugate vaccine
seems to  benefit at least partly from the
immunologic characters of the carrier
protein. The protein is presented as peptides
in association with the major histocompat-
ibility complex class II molecules on the291 Vol. 2, No. 4—October-December 1996 Emerging Infectious Diseases
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surface of the antigen-presenting cells. This
stimulates the T-helper cells, which then
stimulate adjacent B cells for antibody
production and maturation into memory
cells. Development of immunologic memory
means that the protection does not depend
solely on the existing antibody concentra-
tion. Instead, the vaccinated persons can
respond with a rapid, high, and effective
antibody response to colonization or invasion
by the respective Pnc type. Studies in
Finland suggest that this indeed happens:
the efficacy of an Hib conjugate vaccine,
PRP-D, was more than 90% in early infancy,
even though a large proportion of the infants
did not have measurable antibody response
after the primary course of immunization
(25). A study in the United Kingdom suggests
that the carriage of Hib indeed induces a
high “booster type” immune response  (26).
Conjugation of the PS to a protein carrier
has repeatedly been shown to work with Hib;
vaccines based on the same principle would
also decrease the number of different
infections caused by Pnc. Four vaccine
manufacturers have prepared pneumococcal
conjugate vaccines with basically the same
approaches as the Hib conjugates (Table 1).
PncOMPC vaccine contains PSs from seven
serotypes conjugated to the meningococcal
outer membrane protein complex (27). The
PncCRM vaccine contains either oligosac-
charides (OS) or PSs coupled to a nontoxic
mutant diphtheria toxin CRM197. The PS-
containing conjugate vaccine is at present
heptavalent (28), but it is possible to add
types 1 and 5 to the product intended for use
in developing countries. The PncT vaccine
contains eight PSs coupled to tetanus toxoid,
and the PncD product contains the same PSs
coupled to diphtheria toxoid (29). Besides
these formulations, several other approaches
have been tested in animals. These include
conjugates using pneumolysoid (30), pertus-
sis toxin (31), and salmonella protein (32) as
a carrier. Recently, small peptides selected
on the basis of T-cell stimulating properties
have also been coupled to pneumococcal PS
to form conjugate vaccines (33).
Preclinical Testing
Before human trials, these conjugates
were immunogenic and protective in ani-
mals, including mice, infant monkeys, and
chinchillas (34-37). All these studies indicate
that conjugate vaccines have greater immu-
nogenicity than pneumococcal PS vaccines.
Even though animal studies can tell if the
conjugate vaccine is immunogenic and
evokes a T-cell dependent response, the final
proof of conjugate vaccines’ superior immu-
nogenicity and efficacy over PS vaccines
comes only from human studies. So far no
animal model can mimic human immunoge-
nicity and efficacy studies.
Clinical Testing
Pneumococcal conjugates of all the
manufacturers mentioned in Table 1 have
now been tested in phase-I and phase-II
studies. The first human studies were done
in adults with mono- or bivalent conjugates
and showed that the conjugates were at least
as immunogenic as the PS vaccine. Since
then, up to eight valent vaccines have been
used in human studies, also among infants.
Adults and Toddlers
To show that they are safe and
immunogenic, pneumococcal conjugates were
first given to small numbers of adults and
toddlers. Most of the reported studies have
been conducted with mono- to tetravalent
vaccines. The PncOMPC studies in adults
show that the conjugate vaccine was well
tolerated but not more immunogenic than
the PS vaccine (38,39). One possible reason
might be the low dose (1mg to 5mg of each
Table 1. Pneumococcal conjugate vaccines in phase-
II and phase-III trials
Vaccine Serotype Carrier Manufacturer
PncCRM 4, 6B, 9V, CRM197 Wyeth-Lederle
14, 18C, Vaccines and
19F, 23F Pediatrics
PncD 3, 4, 6B, Diphtheria Connaught
9V, 14, 18C, toxoid Laboratories
19F, 23
PncT 3, 4, 6B, Tetanus Pasteur
9V, 14, 18C, toxoid Merieux
19F, 23 Serums &
Vaccins
PncOMPC 4, 6B, 9V, Meningo- Merck
14, 18C, coccal Research
19F, 23F OMPC Laboratories
CRM = CRM197, a nontoxic variant of diphtheria toxin; D =
diphtheria toxoid; T = tetanus toxoid; OMPC = outer
membrane protein complex292 Emerging Infectious Diseases Vol. 2, No. 4—October-December 1996
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conjugate) used in these studies. Different
formulations of PncCRM containing either
PS or OS linked to CRM197 have been tested
in adults. All were well tolerated and evoked
a comparable immune response (40). This
was confirmed in a study in which heptavalent
OS conjugate was immunogenic (28). Results
of immunizing adults with PncT or PncD
conjugates have been reported in two
studies; both vaccines were more immuno-
genic than the PS vaccine (41,42). The
Finnish study with tetravalent PncT and
PncD showed that these conjugates can also
evoke a mucosal antibody response (42).
PncOMPC vaccine was given to 31
Finnish children at 24 months, and 10 of
them also received it at 26 months. The
primary response was only slightly higher
than to the PS vaccine, but after the second
dose a booster type response was seen in
most of the vaccinees (43). Studies conducted
during the second year of life showed that the
heptavalent PncOMPC conjugate was more
immunogenic than the PS vaccine (44,45).
Different formulations of PncCRM have also
been tested in toddlers (46). Conjugates were
more immunogenic than the PS vaccine;
furthermore, the PS conjugate was more
immunogenic than the OS conjugate. One
study showed a good booster response to PS
vaccine after primary immunization with
pentavalent PS-based PncCRM (47). The
PncT and PncD conjugates have also proven
immunogenic in toddlers. A Finnish study
compared 3-mg and 10-mg doses at 24 months,
and a U.S. study used 10-mg doses of type 19F
conjugates with PS vaccine booster doses
(48).
Infants
Keyserling et al. (49) have compared
different dosages of type 14 PS containing
monovalent PncOMPC vaccine in infants and
shown that 2.5mg to 5mg of type 14 PS in the
conjugate gave better responses than the
lower doses. A Finnish study (50) showed
that a primary series of three doses of
tetravalent PncOMPC at 2, 4, and 6 months
was better than two doses at 4 and 6 months.
Furthermore, a booster dose of PncOMPC
given at 14 months evoked a secondary
response to all PS types. Concomitant
administration of PncOMPC with routine
infant immunizations does not seem to have
an effect on either anti-Hib or anti-Pnc PS
antibody responses (51). The heptavalent
PncOMPC formulation is as immunogenic as
the previous formulations with fewer sero-
types (27).
Åhman et al. have shown that the
pentavalent PncCRM vaccine containing OS
derived from pneumococcal capsule was
immunogenic and tolerable in infants (52).
The same children developed a good antibody
response when boostered with PS vaccine at
24 months, suggesting that the immunologic
priming had been good even if the antibody
response to the primary series had remained
rather low  (53). The PS-based PncCRM has
been shown to be more immunogenic than OS
conjugates also in infancy (54). A Gambian
study evaluated the pentavalent PncCRM
conjugate (PS-based) in a developing country
when given at 2, 3, and 4 or at 2 and 4
months. The vaccine was immunogenic and
well tolerated; the schedule of three doses
was better than the two-dose schedule (55).
A Finnish study compared three dosages
of 1mg to 10mg of each PS in tetravalent PncT
and PncD conjugates when administered at
2, 4, and 6 months. These vaccines were
immunogenic in infancy, and no difference
could be shown between PncT and PncD. The
response after a primary series to PncD, but
not to PncT, was dose dependent (56). The
children immunized with PncD in infancy
had a booster response after reimmunization
with either PncD or pneumococcal PS
vaccine at 14 months (57). All who received
PncT were boostered with PS vaccine, and
the response was dose dependent; children
that had received 10-mg doses of PncT during
the primary immunization had the lowest
mean booster responses (58). Another Finn-
ish study showed that octavalent (types 3, 4,
6B, 9V, 14, 18C, 19F, and 23F) PncD (3mg of
each PS) and PncT (1mg of each PS) induced
immune responses similar to the respective
tetravalent formulations (29). An Icelandic
study showed that the octavalent vaccine
was immunogenic in infants when given at 3,
4, and 6 months and that the IgG anti-PS
concentrations correlated with the opsonic
activity (59).
Because no study has directly compared
different pneumococcal conjugate vaccines,293 Vol. 2, No. 4—October-December 1996 Emerging Infectious Diseases
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the comparison has to rely on data from
separate studies. A Finnish group has
analyzed the antibody response in adults,
toddlers, and infants to all four types of Pnc
conjugates. This comparison shows that
there are vaccine- and type-specific differ-
ences in the antibody responses (Table 2).
However, none of the vaccines used in these
studies have the composition suggested in
the phase-III trials  (29,50,52,56).
Comparing the data from different
studies is difficult because there can be
interlaboratory variation in the enzyme-
linked immunosorbent assay results. The
Centers for Disease Control and Prevention,
Food and Drug Administration, and World
Health Organization are working on a
standardized anti-Pnc PS assay, which will,
if not eliminate, at least reduce the impact of
this problem. A standard serum (60) to be
used in all laboratories is distributed by
Center for Biologics Evaluation and Re-
search/Food and Drug Administration.
Pneumococcal Conjugates and the
Carriage of Pnc
Experience with the Hib conjugates (24)
suggests that Pnc conjugate vaccines could
also reduce the number of carriers of the
vaccine types and in this way decrease the
spread of bacteria. The results from the only
reported study are encouraging. The
PncOMPC vaccine decreased the carriage
rate among toddlers, while the pneumococcal
PS vaccine did not (45). Importantly, the
carriage of antibiotic-resistant Pnc also
decreased (61).
Efficacy Studies
Phase-III studies with the heptavalent
formulations of PncOMPC and PncCRM are
ongoing or being started. These studies look
at prevention of carriage, acute otitis media,
or invasive Pnc infection caused by Pnc of the
vaccine serotypes. Furthermore, there are
several plans for studying the effect of Pnc
conjugates on Pnc invasive infection and
pneumonia in developing countries.
Questions to Be Answered in the Future
We do not know if conjugate vaccines can
really prevent Pnc infections better than the
PS vaccine. We hope that the new vaccines
can prevent several types of infections, from
symptomless Pnc carriage to serious inva-
sive infections with high death rates. It is
quite probable that the protective immune
response needed is different for each type of
infection. We do not know if parenterally
administered vaccine can prevent carriage or
mucosal infections such as acute otitis
media. It is still unknown whether a mucosal
immune response is needed or whether
transudation of antibodies from the serum is
enough for protection against local infection.
Saliva samples of infants immunized with
Hib conjugate vaccines contain secretory IgA
but also IgG, which has most probably
Table 2. Antibody response of Finnish infants to pneumococcal conjugate vaccines administered at
2, 4, and 6 months of age*.
Geometric Mean of the Anti-PNC PS (mg/ml)
Type 6B Type 14 Type 19F Type 23F
Vaccine Pre Post Pre Post Pre Post Pre Post Ref.
PncOMPC 0.17 1.30 0.42 8.27 0.34 9.85 0.28 1.90 (50)
PncCRM 0.25 0.50 0.30 2.49 0.46 1.13 0.18 0.83 (52)
PncT01-4 0.25 0.89 0.24 2.84 0.36 3.73 0.18 0.82 (56)
PncT01-8 0.20 1.28 0.30 2.56 0.56 4.23 0.22 1.03 (29)
PncD03-4 0.26 0.88 0.44 2.20 0.43 5.29 0.21 0.67 (56)
PncD03-8 0.17 1.44 0.31 4.62 0.37 4.94 0.24 1.07 (29)
PncOMP = tetravalent conjugate vaccine with a meningococcal outer membrane protein complex as a carrier
PncCRM = pentavalent oligosaccharide conjugate vaccine with CRM197 protein as a carrier
PncT01-4 = tetravalent conjugate vaccine with tetanus toxoid carrier; 1 mg of each of four polysaccharides
PncT01-8 = tetravalent conjugate vaccine with tetanus toxoid carrier; 1 mg of each of four polysaccharides
PncD03-4 = tetravalent conjugate vaccine with diphtheria toxoid carrier; 3mg of each of four polysaccharides
PncD03-8 = octavalent conjugate vaccine with diphtheria toxoid carrier; 3mg of each of four polysaccharides
*Serum samples are taken before immunization (pre) and at 7 months (post).  The data have been gathered
from separate studies done in the same population.294 Emerging Infectious Diseases Vol. 2, No. 4—October-December 1996
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transudated from serum (62). In an infant
rat Hib colonization model, both secretory
IgA and serum derived IgG decreased
colonization (63). Furthermore, animal ex-
periments suggest that immune response
evoked by parenteral administration of a
conjugate vaccine would alone protect
against acute otitis media (64). In addition,
passive immunization of infants with
hyperimmune serum pool containing anti-
bodies to pneumococcal PS-induced protec-
tion against pneumococcal acute otitis media
suggests that protection is offered when high
enough serum antibody concentrations are
gained (65). At present, there are no data to
show which antibody concentrations are
needed for protection. Deciding about the
protective concentration might be difficult
because the development of immunologic
memory is an important factor; the protec-
tion does not solely depend on the existing
antibody concentration.
Most phase-II studies have used a
schedule of two or three doses of Pnc
conjugate vaccine in infancy (usually at 2, 4,
and 6 months) and a booster dose of either
conjugate or Pnc PS at the second year of life.
The need for a booster dose at the second
year is not known; this information would be
important especially for planning the vacci-
nation schedules for developing countries,
where administering a booster dose can be
problematic. The experience from the Hib
conjugates suggests that a booster dose
might not be needed; the United Kingdom
has successfully used a schedule of three
doses at 3, 4, and 5 months without a booster
dose (66).
Reduction of pneumococcal infections
among the elderly would probably increase
the quality of their lives. The immunogenic-
ity of pneumococcal PS vaccine in this age
group has been satisfactory (67,68). An Hib
conjugate (PRP-D) has proven more immuno-
genic than the Hib PS vaccine in the elderly
(69). However, the immune response to
PncCRM was not better than to the Pnc PS
vaccine, and no booster response was seen
(70). Studies with other pneumococcal
conjugates in the elderly have not been
reported.
Because pneumococcal infections of very
young infants are a problem in developing
countries, several groups have studied the
possibility of maternal immunization with
pneumococcal vaccines (71,72). So far only
PS vaccines have been used; even though
these vaccines are immunogenic in pregnant
mothers, the immunity transferred to the
neonate is not very long lasting. If the
conjugate vaccines induce higher antibody
concentrations in mothers, the concentration
of passively acquired antibody in the baby
would stay high for a longer time. The Hib
conjugate vaccines induce good responses in
mothers and, consequently, long-lasting
protective concentrations in infants born to
these mothers (73,74). The effect of simulta-
neous maternal tetanus immunization, espe-
cially if conjugates with a tetanus toxoid
carrier are used, and the effect of high
maternal antibody level on the antibody
responses of the infants have to be
determined.
By the year 2000, we may have pneumo-
coccal conjugate vaccines to include in
routine childhood immunization programs.
The price of the conjugate vaccines has been
so high that their use throughout the world
has not been possible. An important
challenge in developing of pneumococcal
conjugate vaccines is to reduce the costs of
manufacturing so that all children can
benefit from them.
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